NCT05968417RecruitingNot Applicable
Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies
Institute of Cancer Research, United Kingdom1 site in 1 country250 target enrollmentStarted: July 22, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 250
- Locations
- 1
- Primary Endpoint
- Cell viability
Study Overview
Brief Summary
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
- •Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
- •Participants aged 18 years of age or above
- •Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
Exclusion Criteria
- •Participants unable to provide consent
- •Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Outcomes
Primary Outcomes
Cell viability
Time Frame: 12 months
Myeloma cell viability when incubated with standard of care and novel compounds.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Not Applicable
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00897910Barbara Ann Karmanos Cancer Institute6
Completed
Phase 1
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple MyelomaMultiple MyelomaNCT00552396Innate Pharma32
Unknown
Not Applicable
Bone Pain in Multiple Myeloma- a Translational StudyMultiple MyelomaNCT04273425Sheffield Teaching Hospitals NHS Foundation Trust35
Active, not recruiting
Phase 1
A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple MyelomaMultiple MyelomaNCT04499339Wuerzburg University Hospital38
Unknown
Not Applicable
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omicsBortezomibMultiple MyelomaNCT04678089Beijing Chao Yang Hospital350